Dr. Maithel collaborates with a variety of cancer treatment teams to deliver top, multidisciplinary cancer care to Winship patients.
Titles and Roles
- Associate Professor, Division of Surgical Oncology, Department of Surgery
- Emory University School of Medicine
- Research Program
- Discovery and Developmental Therapeutics
Shishir K. Maithel, MD, FACS, joined Emory Healthcare in 2009 and is board certified in surgery. Dr. Maithel's clinical interests include tumors of the liver (metastatic and primary), bile ducts, pancreas, stomach, colon, small intestine, and sarcoma.
Dr. Maithel is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Insitute. He is also a member of the American College of Surgeons, Society for Surgery of the Alimentary Tract, Americas Hepato-Pancreato-Biliary Association, and the Society of Surgical Oncology.
Dr. Maithel earned his medical degree at the University of Chicago, Pritzker School of Medicine graduating Alpha Omega Alpha. He completed his internship and residency at Beth Israel Deaconess Medical Center of Harvard Medical School. Before joining Emory, Dr. Maithel completed a fellowship in both surgical oncology and hepatopancreatobiliary surgery at Memorial Sloan-Kettering Cancer Center in New York.
Dr. Maithel has received numerous awards including the Medical Student Research Award and the Department of Surgery Medical Student Award from the University of Chicago as well as the Outstanding Resident Teaching Award and First Place in the Annual Residents' Research Competition from Harvard Medical School. He is an alumni member of Alpha Omega Alpha Honorary Medical Society.
Dr. Maithel has a variety of research interests. He has worked in clinical investigation and outcomes analysis of patients treated for tumors of the liver, biliary tract, pancreas, and stomach. He also leads the translational research program in the Division of Surgical Oncology that focuses on identifying tumor specific molecular biomarkers as predictors of outcome and chemotherapeutic response for tumors of the liver, biliary tract, pancreas, and stomach (including colorectal liver metastases and pancreas cancer).
Dr. Maithel is also the Principal Investigator on a novel protocol testing the benefit of giving two chemotherapy drugs instead of one after complete resection of pancreatic cancer and is a member and leader of three multi-institutional research consortiums that study tumors of the liver, biliary tract, pancreas, and stomach. He also leads the active research program in the Division of Surgical Oncology aimed at training post-graduate research fellows.